VBI Vaccines, Brii Biosciences Expand Hepatitis B Immunotherapy Pact
Portfolio Pulse from Vandana Singh
VBI Vaccines Inc has expanded its hepatitis B partnership with Brii Biosciences. Brii Bio has acquired a worldwide exclusive license for VBI-2601 and an exclusive license for PreHevbri in the Asia Pacific region from VBI. Brii Bio will pay VBI an upfront payment of $15 million, including an equity investment of approximately $3 million, contingent on achieving near-term milestones. VBI is also eligible to receive up to an additional $422 million in potential regulatory and commercial milestone payments and double-digit royalties in the licensed territories worldwide for VBI-2601 and APAC, excluding Japan, for PreHevbri. VBIV shares are down 28.50% at $1.73 during the premarket session on the last check Thursday.
July 06, 2023 | 11:38 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
VBI Vaccines has expanded its partnership with Brii Biosciences, granting exclusive licenses for VBI-2601 and PreHevbri. This could potentially bring in significant revenue for VBI Vaccines, but the company's shares are currently down.
The expanded partnership and licensing agreements with Brii Biosciences could potentially bring in significant revenue for VBI Vaccines, which is a positive development for the company. However, the company's shares are currently down, indicating a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100